Dashboard
Transgene (Euronext: TNG)
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s clinical-stage programs are: TG4001, a therapeutic vaccine against HPV-positive head and neck cancers, TG6002, an oncolytic virus for the treatment of solid tumors, TG4050, the first individualized therapeutic vaccine based on the myvac™ platform and BT-001, the first oncolytic virus based on the Invir.IO™ platform.
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Corporate presentation (May 2020)
Press releases
- May 15, 2020 - Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
- May 15, 2020 - Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
- May 6, 2020 - Transgene reports Q1 2020 financial position and business update
Financial reports
Financial calendar
- March 11, 2020 - 2019 Fiscal Year Results
- May 6, 2020 - First Quarter 2020 Financial Results
- May 27, 2020 - Annual Shareholders’ Meeting
- September 16, 2020 - First Half 2020 Financial Results
- November 6, 2020 - Third Quarter 2020 Financial Results
Contact
Contact Relations Investisseurs
Lucie Larguier, +33 (0)3 88 27 91 00,
Financial information
Key figures
| In € million except share and per share data | 2019 | 2018 | 2017 | 2016 | 2015 |
| Revenue | 13.7 | 42.9 | 8.1 | 10.3 | 9.9 |
| R&D Expense | -31.4 | -27.3 | -30.4 | -26.4 | -32.1 |
| G&A Expense | -7.1 | -7.0 | -5.7 | -6.2 | -5.8 |
| Net income (loss) | -18.8 | 8.0 | -32.3 | -25.2 | -46.4 |
| Net Cash Burn | -20.5 | -24.5 | -28.1 | -30.6 | -34.8 |
| Cash & Cash Equivalents | 43.3 | 16.9 | 41.4 | 56.2 | 31.6 |
| Earnings/Loss per Share (Basic and Diluted) | -0.23 | 0.13 | -0.52 | -0.45 | -1.20 |
| Shares Outstanding | 83,265,464 | 62,275,923 | 62,075,190 | 56,431,991 | 38,545,397 |
Financial reports
Regulated information
Monthly information on shares outstanding and voting rights (in French)
Share buyback program (in French)
Liquidity contract related information
Half-year report on the Transgene liquidity contract
Chairman’s report on corporate governance and internal controls
Annual General Meeting information
- May 22, 2019: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in french)
- May 23, 2018: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in french)
- June 8, 2017: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in french)
- May 24, 2016: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in french)
- June 11, 2015: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in french)
- June 18, 2014: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in french)
Rights issue
Stock information
| Company | Analyst | Phone | |
|---|---|---|---|
| Bryan Garnier & Co. Ltd | Jean-Jacques Le Fur | jjlefur@bryangarnier.com | +33 (0)1 70 36 57 45 |
| Invest Securities | Thibaut Voglimacci-Stephanopoli | tvoglimacci@invest-securities.com | +33 (0)1 44 88 88 09 |
| Kempen & Co. | Suzanne van Voorthuizen | suzanne.vanvoorthuizen@kempen.com | +31 (0)20 348 8484 |
| Kepler Cheuvreux | Arsene Guekam | aguekam@keplercheuvreux.com | +33 1 70 98 85 27 |
| Life Science Capital LLC | Jacques A. Villefranc | jacques@lifesciadvisors.com | +1 646 597-6997 |
| Oddo BHF | Martial Descoutures | martial.descoutures@oddo-bhf.com | +33 (0)1 44 51 85 00 |
Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.
Investor Events & Presentations
Presentations
Financial calendar
- March 11, 2020 - 2019 Fiscal Year Results
- May 6, 2020 - First Quarter 2020 Financial Results
- May 27, 2020 - Annual Shareholders’ Meeting
- September 16, 2020 - First Half 2020 Financial Results
- November 6, 2020 - Third Quarter 2020 Financial Results
Investor events
- January 9, 2020 - Oddo Forum: January 9 & 10, 2020 – Lyon, France
- January 13, 2020 - J.P. Morgan Healthcare Conference: January 13 to 16, 2020 – San Francisco, USA
- January 28, 2020 - Biomed Event: January 28, 2020 – Paris, France
Corporate governance
Transgene complies with the corporate governance recommendations of the MiddleNext Code of Governance for Mid and Small Caps (the Code) (Code de gouvernement d’entreprise des valeurs moyennes et petites de MiddleNext). MiddleNext is an independent society representing midcap public issuers; the Code is largely referred to by small, mid and even large cap firms and accepted by regulators as guidance for best governance practices.
Board of Directors
The Board of Directors is currently composed of ten members, elected for renewable three-year terms. Six members of the Board are independent directors as defined in the Code. The Board is chaired by the Chairman and Chief Executive Officer. The Board has adopted a charter of internal regulations that governs the conduct of the Board of Directors and its committees. Detailed information can be found in the Registration Document.
The Board of Directors is assisted by two committees:
The Audit Committee is composed of four directors of the Board, three of whom are independent. The Vice President Finance is invited to attend each Committee meeting to present the financial situation of the Company. The Audit Committee’s operations are governed by a charter that is reviewed regularly. The committee regularly reports on its work and provides recommendations to the Board of Directors.
The Compensation Committee is composed of two independent directors and is responsible for recommending to the Board of Directors the salaries, bonuses and share-based compensation to executives and key personnel of the Company.
Management Committee
The Management Committee is a non-statutory body that oversees the Company’s daily operations and ensures, in all managerial aspects, that the Company’s strategy is properly executed in accordance with its objectives. The committee is composed of nine members
The Company has established a number of other internal bodies and procedures, for example, for financial controlling, project management and risk management.
- Rules of procedure of the Board of Directors (in French)
- Bylaws
- Rules of procedure of the audit committee of the Board of Directors (in French)
- Rules of procedure of the compensation committee of the Board of Directors (in French)
- Rules of procedure of related party agreements and commitments (in French)
Annual General Meeting
Annual General Meeting of May 27, 2020
ORDINARY AND EXTRAORDINARY MEETING
Location
TRANSGENE
400 boulevard Gonthier d’Andernach – Parc d’Innovation
67400 ILLKIRCH-GRAFFENSTADEN – FRANCE
Date and Time
27 May 2020 at 10am
Documents